OCULAR THERAPEUTIX, INC Fair Value Adjustment of Warrants
OCULAR THERAPEUTIX, INC (OCUL) reported Fair Value Adjustment of Warrants of $380.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2017-03-10.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2017-03-10
- OCULAR THERAPEUTIX, INC fair value adjustment of warrants for the quarter ending 2014-12-31 was $0.00.
- OCULAR THERAPEUTIX, INC fair value adjustment of warrants for the quarter ending 2014-09-30 was $108.00K.
- OCULAR THERAPEUTIX, INC fair value adjustment of warrants for the quarter ending 2014-06-30 was $131.00K.
- OCULAR THERAPEUTIX, INC fair value adjustment of warrants for the quarter ending 2014-03-31 was $141.00K.
- OCULAR THERAPEUTIX, INC fair value adjustment of warrants for fiscal 2014 was $380.00K.
- OCULAR THERAPEUTIX, INC fair value adjustment of warrants for fiscal 2013 was -$14.00K, a 128.57% decline from fiscal 2012.
- OCULAR THERAPEUTIX, INC fair value adjustment of warrants for fiscal 2012 was $49.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $108.00K derived: sum of 2 quarters · filed 2017-03-10 | $239.00K derived: sum of 3 quarters · filed 2017-03-10 | $380.00K 10-K · filed 2017-03-10 |
| 2014-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $239.00K derived: sum of 2 quarters · filed 2015-11-10 | $380.00K 10-Q · filed 2015-11-10 | $376.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $131.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $272.00K 10-Q · filed 2015-08-10 | $268.00K derived: sum of 3 quarters · filed 2016-03-10 | $265.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $141.00K 10-Q · filed 2015-05-15 | $137.00K derived: sum of 2 quarters · filed 2016-03-10 | $134.00K derived: sum of 3 quarters · filed 2016-03-10 | |
| 2013-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | -$7.00K derived: sum of 2 quarters · filed 2016-03-10 | -$14.00K 10-K · filed 2016-03-10 | |
| 2013-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$10.00K 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | -$7.00K 10-Q · filed 2014-08-29 | |||
| 2012-12-31 | $49.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |